Classification of bioinks by type underpins the market taxonomy and influences formulation cost, print fidelity, and post‑printing functionality. Natural polymer‑based bioinks—including alginate, gelatin methacryloyl (GelMA), and hyaluronic acid—represent the largest share, roughly 45 %, because of their inherent biocompatibility and cell‑adhesive motifs, though they often require rheological modifiers to achieve printable viscosities. Synthetic polymer‑based bioinks, such as polyethylene glycol (PEG) derivatives and polycaprolactone (PCL) inks, contribute about 30 %; they offer tunable mechanical properties and controlled degradation but lack intrinsic bioactivity, prompting hybridization strategies. Composite bioinks combine natural and synthetic components, accounting for roughly 15 % of sales, delivering balanced printability and biological performance. A niche yet rapidly expanding segment is decellularized extracellular matrix (dECM) bioinks, which supply tissue‑specific biochemical cues and currently occupy around 7 % of the market. Finally, cell‑laden bioinks—formulations pre‑mixed with living cells—represent approximately 3 % of revenue, reflecting higher handling complexity and regulatory scrutiny. These type categories collectively shape R&D investment and supply‑chain dynamics within the bioinks market.
